What is ACT Genomics Taiwan?
ACT Genomics Taiwan operates at the intersection of tumor biology, cancer genomics, and bioinformatics, providing a comprehensive suite of precision medicine services. The company specializes in actionable insights for solid tumors, offering critical guidance on treatment pathways, relapse monitoring, and drug resistance profiling. By leveraging advanced genomic sequencing and proprietary analytical platforms, ACT Genomics enables clinicians to tailor immunotherapy and targeted therapies to individual patient profiles, thereby improving therapeutic outcomes.
The company's market position is defined by its rigorous approach to cancer monitoring and risk assessment. By bridging the gap between raw genomic data and clinical application, ACT Genomics has established itself as an essential partner for healthcare providers seeking to implement evidence-based precision medicine protocols. Their multi-regional presence allows for the standardization of high-quality diagnostic services across diverse healthcare systems.
How much funding has ACT Genomics Taiwan raised?
ACT Genomics Taiwan has raised a total of $20.5M across 2 funding rounds:
Series A
$8M
Series B
$12.5M
Series A (2015): $8M, investors not publicly disclosed
Series B (2016): $12.5M led by President International Development and UMC Capital
Key Investors in ACT Genomics Taiwan
President International Development
President International Development Corporation serves as the investment holdings arm of the Uni-President Group, focusing on strategic capital allocation across diverse sectors including finance and international trade.
UMC Capital
UMC Capital is the investment division of a leading global semiconductor foundry, providing strategic backing to high-growth technology and biotechnology firms.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ACT Genomics Taiwan?
With the recent capital deployment, ACT Genomics is well-positioned to accelerate its research and development initiatives, particularly in the refinement of its bioinformatics pipelines and the expansion of its clinical diagnostic portfolio. The strategic focus will likely shift toward deepening its penetration in existing markets while exploring new opportunities for collaborative research in immunotherapy evaluation.
As the oncology diagnostics sector continues to evolve, the company's emphasis on data-driven treatment guidelines will remain a core competitive advantage. Future growth will be predicated on the successful integration of real-world evidence into their diagnostic frameworks, ensuring that ACT Genomics remains at the forefront of the global shift toward personalized cancer care. The firm is expected to leverage its current financial stability to forge deeper partnerships with pharmaceutical entities and clinical research organizations.
